Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Stephanie A Vuijk, Maria M E Jongsma, Britt M Hoeven, Maarten A Cozijnsen, Merel van Pieterson, Tim G J de Meij, Obbe F Norbruis, Michael Groeneweg, Victorien M Wolters, Herbert van Wering, Thalia Hummel, Janneke Stapelbroek, Cathelijne van der Feen, Patrick F van Rheenen, Michiel P van Wijk, Sarah Teklenburg, Dimitris Rizopoulos, Marten J Poley, Johanna C Escher, Lissy de Ridder
BACKGROUND: Data on cost-effectiveness of first-line infliximab in paediatric patients with Crohn's disease are limited. Since biologics are increasingly prescribed and accompanied by high costs, this knowledge gap needs to be addressed. AIM: To investigate the cost-effectiveness of first-line infliximab compared to conventional treatment in children with moderate-to-severe Crohn's disease. METHODS: We included patients from the Top-down Infliximab Study in Kids with Crohn's disease randomised controlled trial...
April 21, 2024: Alimentary Pharmacology & Therapeutics
#2
JOURNAL ARTICLE
Stefano Kayali, Stefano Fantasia, Federica Gaiani, Lucas Giovanni Cavallaro, Gian Luigi de'Angelis, Luigi Laghi
Crohn's disease (CD) is a chronic inflammatory bowel disease with a multifactorial pathogenesis involving environmental and genetic factors. Since the late 20th century, the discovery of the first susceptibility gene (NOD2, previously referred to as CARD15) for CD has paved the way for further investigations into the correlations between clinical features and genetics, and its potential impact on clinical practice has fueled the research in the last 2 decades. Recent therapeutic advancements involving novel biologic drugs and small molecules have shifted inflammatory bowel disease management from a disease-centered to a patient-centric approach...
April 6, 2024: Inflammatory Bowel Diseases
#3
JOURNAL ARTICLE
M Kooffreh-Ada, E Chukwudike, T Ugbem, A E Itam-Eyo, O Uba-Mgbemena, I E Nwa, B A Eko, E I Effiong, A J Omotoso, G Kajogbola, U C Okonkwo, O E Ngim, R Ndoma-Egba
BACKGROUND: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract that is reported to be rare in Africans. The objective of this study is to share the experience of our Gastroenterology practice in Calabar, Cross River State on IBD. METHODS: This is a ten-year review of the records of patients visiting the Gastroenterology clinic of the University of Calabar Teaching Hospital and two private gastroenterology clinics in Calabar Municipality...
February 29, 2024: West African Journal of Medicine
#4
JOURNAL ARTICLE
Swathi Suyamburajan, Rama Bhat, Raghavendra Rao, Srilatha Srilatha Parampalli
Autoimmune disorders have a wide spectrum of symptoms, often with multiorgan involvement. Multiple autoimmune disorders also often occur concurrently in the same patient. These two possibilities must be distinguished in patients with multiorgan involvement to ensure early diagnosis and treatment. Here, we report a case of a previously healthy man who presented with simultaneous Takayasu arteritis and Crohn's disease. He presented with heart failure with reduced ejection fraction and severe aortic regurgitation...
March 26, 2024: BMJ Case Reports
#5
JOURNAL ARTICLE
Mansour Altuwaijri, Nasser Alkhraiji, Mosaab Almasry, Saad Alkhowaiter, Nuha Al Amaar, Ammar Alotaibi
Crohn's disease (CD) is an inflammatory disease that can affect any part of the gastrointestinal tract and presents with myriad symptoms. Various treatments, including biological treatments, are available. The use of biologics increases the risk of opportunistic infections, with no association with serious infections (1). To the best of our knowledge, there are no established recommendations or case studies for patients with CD infected with Brucella being actively treated with biologics and immunomodulators to date...
March 21, 2024: Arab Journal of Gastroenterology: the Official Publication of the Pan-Arab Association of Gastroenterology
#6
JOURNAL ARTICLE
Francisco Mesonero, Yamile Zabana, Agnès Fernández-Clotet, Eduardo Leo-Carnerero, Berta Caballol, Andrea Núñez-Ortiz, María José García, Federico Bertoletti, Alejandro Mínguez, Gerard Suris, Begoña Casis, Rocío Ferreiro-Iglesias, Margalida Calafat, Itxaso Jiménez, José Miranda-Bautista, Luis Javier Lamuela, Ingrid Fajardo, Leyanira Torrealba, Rodrigo Nájera, Rosa María Sáiz-Chumillas, Irene González, Miren Vicuña, Natalia García-Morales, Ana Gutiérrez, Alicia López-García, José Manuel Benítez, Cristina Rubín de Célix, Coral Tejido, Eduard Brunet, Alejandro Hernández-Camba, Cristina Suárez, Iago Rodríguez-Lago, Marta Piqueras, Andrés Castaño, Laura Ramos, Ana Sobrino, María Carmen Rodríguez-Grau, Alfonso Elosua, Miguel Montoro, Ruth Baltar, José María Huguet, Benito Hermida, Antonio Caballero-Mateos, Luis Sánchez-Guillén, Abdel Bouhmidi, Ramón Pajares, Iria Baston-Rey, Antonio López-Sanromán, Agustin Albillos, Manuel Barreiro-de Acosta
BACKGROUND: The usefulness of thiopurines has been poorly explored in pouchitis and other pouch disorders. OBJECTIVE: To evaluate the effectiveness and safety of azathioprine as maintenance therapy in inflammatory pouch disorders. DESIGN: This was a retrospective and multicentre study. METHODS: We included patients diagnosed with inflammatory pouch disorders treated with azathioprine in monotherapy. Effectiveness was evaluated at 1 year and in the long term based on normalization of stool frequency, absence of pain, faecal urgency or fistula discharge (clinical remission), or any improvement in these symptoms (clinical response)...
2024: Therapeutic Advances in Gastroenterology
#7
JOURNAL ARTICLE
Helena Gensmyr-Singer, Mårten Werner, Pontus Karling
BACKGROUND: Thiopurines are commonly used to treat inflammatory bowel disease but withdrawal due to side effects are common. Thioguanine has been suggested to be better tolerated than conventional thiopurines. OBJECTIVES: We studied drug-survival of low dose of thioguanine in real-life clinical practice in comparison to conventional thiopurines. DESIGN: Retrospective observational study. METHODS: All patients born 1956 and later, and who at least once started thiopurine treatment between 2006 and 2022 were included...
2024: Therapeutic Advances in Gastroenterology
#8
REVIEW
Ahmed B Bayoumy, Chris J J Mulder, Azhar R Ansari, Murray L Barclay, Tim Florin, Marianne Kiszka-Kanowitz, Luc Derijks, Vishal Sharma, Nanne K H de Boer
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract that encompasses two major conditions: Crohn's disease (CD) and ulcerative colitis (UC). Historically, IBD has been primarily reported in western countries, but over the past decades, its prevalence is rapidly increasing, especially in lower and middle-income countries (LMICs) such as India and China and also in Sub-Saharan Africa. The prevalence of IBD in LMICs has been the subject of growing concern due to the impact of access to public healthcare and the burden it places on healthcare resources...
February 21, 2024: Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology
#9
JOURNAL ARTICLE
Akihito Saito, Miho Nara, Takashi Fujishima, Wataru Kuroki, Takaya Yamashita, Takahiro Kobayashi, Sho Ikeda, Akihiro Kitadate, Yoshihiro Kameoka, Naoto Takahashi
The patient was a 21-year-old man who had been diagnosed with Crohn's disease and received infliximab and azathioprine six years earlier. He was admitted with fever and fatigue. Peripheral blood examination showed LDH 2,473 U/l and thrombocytopenia, and contrast-enhanced computed tomography (CT) showed hepatosplenomegaly. Bone marrow biopsy and liver biopsy showed CD4+CD56+TCRγδ＋CD8- atypical cells, leading to a diagnosis of hepatosplenic T-cell lymphoma (HSTCL). The patient was refractory to CHOP and DA-EPOCH, and therefore received cord blood transplantation with myeloablative conditioning...
2024: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
#10
JOURNAL ARTICLE
Ming Duan, Mengjie Lu, Yanqing Diao, Lei Cao, Qiong Wu, Yuxiu Liu, Jianfeng Gong, Weiming Zhu, Yi Li
BACKGROUND: Azathioprine (AZA) effectively prevents postoperative endoscopic recurrence (ER) in Crohn's disease (CD). However, the efficacy of AZA emerge needs 3 months. Exclusive enteral nutrition (EEN) can maintain remission for CD. The trial investigates whether AZA plus postoperative 3-month EEN is superior to AZA alone in preventing ER of CD. METHODS: Totally, 84 high-risk CD patients undergoing intestinal resection received AZA alone or AZA plus a 3-month EEN (AZA+EEN) postoperatively...
January 22, 2024: Journal of Crohn's & Colitis
#11
JOURNAL ARTICLE
Yumiko Nakamura, Yuichiro Kawai, Sumiko Nagoshi, Tomonari Ogawa, Hajime Hasegawa
BACKGROUND: Inflammatory bowel disease involves chronic inflammation and ulceration, primarily Crohn's disease and ulcerative colitis. The prevalence of inflammatory bowel disease is rising in industrialized countries. We describe the case of a patient with inflammatory bowel disease and multiple electrolyte disturbances that emphasize the link between a vitamin D deficiency and electrolyte imbalances. CASE: An 86-year-old Japanese man with severe hypocalcemia, hypophosphatemia, hypokalemia, and hypomagnesemia was referred to the gastroenterology and hepatology department our university hospital for severe diarrhea and abdominal pain...
January 22, 2024: Journal of Medical Case Reports
#12
JOURNAL ARTICLE
Ruben J Colman, Stephanie A Vuijk, Ron A A Mathôt, Johan Van Limbergen, Maria M E Jongsma, Marco W J Schreurs, Phillip Minar, Lissy de Ridder, Geert R A M D'Haens
BACKGROUND: The use of concomitant azathioprine may improve efficacy and pharmacokinetic (PK) properties of infliximab (IFX) but is also associated with an increased risk of adverse events. Proactive therapeutic drug monitoring (pTDM) of IFX monotherapy is an alternative strategy to improve PK. The aim of this study was to evaluate whether IFX with an immunomodulator (combo) has PK benefits over IFX-pTDM (mono) in pediatric Crohn's disease (CD). METHODS: This PK analysis included pediatric CD patients who started either IFX combo (TISKids study) or IFX mono with pTDM (REFINE cohort)...
January 3, 2024: Inflammatory Bowel Diseases
#13
JOURNAL ARTICLE
Cæcilie Skejø, Signe Thim, Anna Sellmer, Mette Julsgaard
No abstract text is available yet for this article.
December 23, 2023: Inflammatory Bowel Diseases
#14
Nadeer Kottavadakkeel, Reefat Farzina, Arun Rajaram, Sathia Mannath, Abida Sunil
Inflammatory bowel disease (IBD) is an autoimmune disorder marked by chronic inflammation affecting the intestines. Crohn's disease (CD) and ulcerative colitis (UC) fall under the IBD umbrella, necessitating diverse treatments, including steroids, immunomodulators like 6-mercaptopurine (6-MP) and azathioprine (AZA), and biological agents. The prolonged use of immunomodulators, such as AZA, is associated with an elevated risk of developing lymphomas. This case report centers on a 77-year-old gentleman regularly monitored by Gastroenterology, undergoing long-term AZA therapy for CD management...
December 2023: Curēus
#15
JOURNAL ARTICLE
Bindu Challa, Ashwini Kumar Esnakula
AIMS: Ocrelizumab is a humanized anti-CD20-monoclonal antibody that has recently been approved for the treatment of certain types of multiple sclerosis. Isolated case reports of ocrelizumab-associated colitis have been reported in the literature. We present a case series of ocrelizumab-associated intestinal injury with a focus on histopathologic features and report a case of ocrelizumab-associated hepatitis. METHODS AND RESULTS: A retrospective computerized search was conducted from 03/2017 to 08/2022, which identified six patients with suspected or clinically confirmed ocrelizumab-associated intestinal injury and one patient with hepatic injury...
December 19, 2023: Histopathology
#16
JOURNAL ARTICLE
M Valvano, A Vinci, N Cesaro, S Frassino, F Ingravalle, M Ameli, A Viscido, S Necozione, G Latella
BACKGROUND: The introduction of biological drugs has led to great expectations and growing optimism in the possibility that this new therapeutic strategy could favourably change the natural history of Inflammatory Bowel Disease (IBD) and, in particular, that it could lead to a significant reduction in surgery in the short and long term. This study aims to assess the impact of biological versus conventional therapy on surgery-free survival time (from the diagnosis to the first bowel resection) and on the overall risk of surgery in patients with Crohn's disease (CD) who were never with the surgical option...
December 14, 2023: BMC Gastroenterology
#17
JOURNAL ARTICLE
Andreia Rei, Irina Mocanu, Carlos Pontinha, Isabel Medeiros
This case reports illustrates a 44-year-old Caucasian male with ileal Crohn´s disease under combined immunosuppression that first presented with unspecific constitutional symptoms, newly pancytopenia and elevated inflammatory markers. The infectious screening was negative except for an ileal abscess that resolved with conservative antibiotic therapy. Due to concerns for lymphoproliferative disease in a patient under anti-TNF and azathioprine, a myelogram was performed that ruled out dysplastic changes...
November 30, 2023: Revista Española de Enfermedades Digestivas
#18
JOURNAL ARTICLE
Klaudia Miklusiak, Karol Miklusiak, Olga Kaczmarczyk, Dorota Cibor, Małgorzata Zwolińska-Wcisło
Pyoderma gangrenosum (PG) is an auto-inflammatory dermatosis characterized by lesions that often cause ulcers. We present a case of successful ustekinumab treatment for acute general PG in a 31-year-old woman with coexisting Crohn's disease (CD). For a month, the patient suffered from skin ulcers, two of them deep and necrotic; a histopathological examination revealed PG. Treatment included: methylprednisolone, azathioprine, betamethasone, gentamicin and zincic ointments, antiseptic compresses, and adalimumab therapy...
September 12, 2023: Dermatology Reports
#19
Xiying Zhao, Jiahao Mo, Beiping Zhang, Haiyan Zhang
At the time of the spread of the COVID-19 epidemic, blurred lung signs suggested by imaging examination are particularly common. Novel coronavirus infection is mainly caused by respiratory symptoms. In the early stage of imaging examination, multiple small patchy shadows or ground glass shadows and invasive shadows of both lungs are dominant. While the pulmonary involvement in Crohn's disease (CD) is rare and not widely reported. For CD patients, the pulmonary manifestations do not belong to its routine symptoms...
2023: Frontiers in Medicine
#20
Ana S Pereira, Inês Coutinho
Metastatic Crohn's disease (MCD) is a rare cutaneous manifestation of Crohn's Disease (CD), defined as non-caseating, granulomatous skin lesions non-contiguous with the gastrointestinal (GI) tract. Most patients with MCD either have concomitant classic manifestations of CD or develop them within a few months to years. We report a case of MCD without known involvement of the GI tract, after more than three years from diagnosis. After failure or intolerance to several conventional treatments, including oral corticosteroids and azathioprine, adalimumab was initiated with a good response...
September 2023: Curēus
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
